UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2018

CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-51173**	**56-2020050**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

260 Littlefield Ave. **South San Francisco, California** **(Address of principal executive offices)**	**94080** **(Zip Code)**

(650) 871-0761
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

On February 12, 2018, Catalyst Biosciences, Inc. is delivering a presentation at the BIO CEO & Investor Conference in New York, NY. A copy of the presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation at the BIO CEO & Investor Conference in New York, NY by Catalyst Biosciences, Inc. on February 12, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATALYST BIOSCIENCES, INC.

Date: February 12, 2018

/s/ Fletcher Payne

Fletcher Payne
Chief Financial Officer

Exhibit 99.1

Catalyst Biosciences

Nasdaq: CBIO

CATALYST BIOSCIENCES

Essential Medicines for Hemophilia • Greater Convenience • Superior Outcomes

12 February 2018

Forward Looking Statements

This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this presentation are forward-looking statements. Examples of such statements include, but are not limited to, the potential benefits of subcutaneous administration of CB 2679d and marzeptacog alfa (activated), the potential for long-term dosing of CB 2679d to maintain FIX activity in the high-mild hemophilia range, statements relating to Catalyst's clinical trial timelines, including plans for patient enrollment of the Phase 2/3 trial of marzeptacog alfa (activated) and the anticipated announcement of interim trial results in the first half of 2018, and plans for the initiation of a Phase 2b clinical trial of CB 2679/d, and the potential market opportunities for these products. Actual results or events could differ materially from the plans and expectations and projections disclosed in these forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the risk that trial initiation may be delayed and that trials and enrollment may be delayed and may not have satisfactory outcomes, that subsequent clinical trials will not replicate the results from initial clinical studies on small numbers of patients and that human clinical trials will not replicate the results from earlier animal trials, that subcutaneous dosing of marzeptacog alfa (activated) may not provide a therapeutic response, that potential adverse effects may arise from the testing or use of Catalyst's products, including the generation of antibodies or inhibitors, the risk that costs required to develop or manufacture Catalyst's products will be higher than anticipated, competition, our ability not to infringe third party intellectual property rights, and other factors described in the "Risk Factors" section of Catalyst's Annual Report on Form 10-K for the year ended December 31, 2016, and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017, June 30, 2017 and September 30, 2017. Forward-looking statements speak only as of the date the statements are made. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.

Preventing Bleeding with Convenient Subcutaneous Dosing

Hemophilia is a large & growing market

- Orphan hematology disease
- FVIIa & FIX products have $3.4B in annual sales

Two novel clinical stage product candidates differentiated from IV market leaders

- Simpler, less painful, small dose
- Potential to maintain continuous protective levels
- Disruptive to all current intravenous products
- Especially well suited for children, 40% of market

FIX: CB 2679d/ISU304

- Phase 1/2 complete
- 22-fold more potent than BeneFIX®
- Daily SQ dosing achieved rising factor levels that correlate with reduced annual bleed rates
- **Corrected all 5 patients from severe to mild hemophilia with only 6 daily SQ doses**
- Less frequent dosing possible
- Phase 2b to initiate in 2018

FVIIa: Marzeptacog alfa (activated)

- Phase 1/2 complete
- 9-fold more potent than NovoSeven®
- Phase 2/3 clinical trial enrolling
- Interim Phase 2 data in H1 2018

Catalyst Biosciences Pipeline



Products & Intellectual Property

Coverage in all Major-Markets & Asia

CATALYST BIOSCIENCES

Factor VIIa: Marzeptacog alfa (activated)



- Worldwide patents cover MarzAA and related molecules
- Granted and pending through **2029** without extensions
- Orphan Drug Designation in **US**

Factor IX: CB 2679d/ISU304



- Worldwide patents cover CB 2679d and related molecules
- Granted and pending through **2031** without extensions
- Orphan Drug Designation in **US & EU**

Experienced Leadership & Investors

CATALYST BIOSCIENCES

Leadership Team

Nassim Usman, Ph.D.
President & Chief Executive Officer
– *MIT, Ribozyme Pharma, Sirna Therapeutics, Morgenthaler Ventures*

Howard Levy, M.B.B.Ch., Ph.D., M.M.M.
Chief Medical Officer
– *Lilly, Novo Nordisk, Sangart, Inspiration, CSL*

Fletcher Payne
Chief Financial Officer
– *IBM, Cell Genesys, Abgenix, Dynavax, Rinat, Plexxikon, CytomX*

Andrew Hetherington, M.B.A.
Sr. VP, Technical Operations
– *GSK, Bayer, Novartis*

Arwa Shurrab
VP, Regulatory Affairs
– *Baxter, Baxalta, Shire*

Jeffrey Landau, M.B.A.
VP, Business Development
– *Jazz Pharmaceuticals, Orphan Medical, Eli Lilly, Onyx, Threshold*

Investors

SIO CAPITAL MANAGEMENT LLC
Venrock
venBio
JG&C J. GOLDMAN & CO., L.P.
RTW Investments
ACUTA
BLACKROCK®
NEXTHERA CAPITAL HEALTHCARE ASSET MANAGEMENT
EW EssexWoodlands
Vanguard®
Johnson & Johnson DEVELOPMENT CORPORATION
HealthCare VENTURES

Advantages of Subcutaneous Prophylaxis

CATALYST BIOSCIENCES

Intravenous Delivery



"I started helping Mom and Dad with the treatment…I don't want to try to get the needle in the vein yet. Maybe when I'm ten."

- Intravenous infusion through painful needle stick
- Requires supervision and skilled insertion of needle into vein
- Challenging for patient, family, school
- Activity levels fluctuate, low trough levels

Subcutaneous Prophylaxis Delivery

Pediatric use of subcutaneous delivery is common for diabetes & HGH deficiency, regularly self-administered

- Subcutaneous injections are easier
- Home therapy - family or patient
- Potential for:
  - Fewer bleeds, reduce joint and muscle damage
  - Fewer demands on healthcare system
  - Reduced hospital stays & outpatient visits

Subcutaneous Administration may be a Superior Prophylaxis Regimen Compared with IV Agents

Time in Mild Predicts Protection from Spontaneous Bleeds



~40+% of Individuals with Hemophilia are Children:
KOL's, Individuals & Treaters Want a Better Dosing Method

FIX $1.2B Market
Treatable Population 9,700



$2.2B FVIIa Market,
Treatable Population ~3,000



Sources: GlobalData, WFH 2015 Survey, CBIO market Research

What Do FIX Key Opinion Leaders Say…

"These exciting results demonstrate for the first time the feasibility of a subcutaneous FIX injection to provide meaningful protection from bleeding, even after only six doses,"

Dr. John Pasi, *Professor of Haemostasis &Thrombosis at Barts and The London School of Medicine*

What Do Inhibitor Key Opinion Leaders Say…

"(MarzAA) would become 1st line treatment for all hemophilia B inhibitor patients."

"(MarzAA) would conservatively capture >10% hemophilia A inhibitor patients, not every patient will go on, or stay on ACE910."

"Severe FVII deficient patients would want to switch to MarzAA… a daily SQ could 'normalize' them"

Factor IX Program: CB 2679d/ISU304

Phase 1/2 Open Label IV to SQ Cross-Over Design

- N = 11
- Ascending Dose Cohorts followed by Multi-dose SQ Cohort

- Cohorts 1-3 & 5 completed
- 6 daily SQ doses corrects severe hemophilia to mild hemophilia with six daily doses[1]
- Well tolerated
- No inhibitors detected



[1]You, Levy *et al*. EAHAD 2018

Cohort 5 FIX Activity Results (140 IU/kg daily SQ)

Six Days of Dosing With Five Days Follow-up (n=5)





- 4/5 subjects had trough levels >12%, sufficient to protect from spontaneous hemarthrosis
- Median 15.7% FIX activity levels [IQR 14.9-16.6%] reached after 6 daily doses
- Median half-life is 63.2 hours [IQR 60.2-64.0]

Phase 1/2 Safety

- Cohort 5
  - Mild injection site adverse events that resolved without sequelae were reported
    - Pain
    - Erythema
    - Redness
  - One subject reported these AEs as moderately severe for the first and second injection and mild for subsequent injections
  - Injection site bruising was seen with initial SQ injections in 2 subjects and did not occur with subsequent injections when FIX activity levels increased to mild hemophilia range
- Entire study:
  - No inhibitory antibodies to CB 2679d/ISU304 or FIX were detected

CB 2679d/ISU304 Program Conclusions

- CB 2679d/ISU304 was designed as a best-in-class high potency recombinant Factor IX
- 22-fold potency advantage *vs* BeneFIX allows subcutaneous administration
- SQ delivery significantly increases half-life to 63.2 hours
- Daily SQ dosing of 140 IU/kg for 6 days resulted in median 15.7% FIX activity and is more convenient compared with all IV FIX approved products
- At the observed rate of increase, higher levels may potentially be achieved over time
- Decreased frequency may be feasible once target activity level achieved
- No inhibitory antibodies to CB 2679d/ISU304 or FIX were detected
- Phase 2b study will explore:
  - Reduced frequency of dosing
  - IV loading dose to increase collagen IV saturation more rapidly and increase bioavailability

Factor VIIa: Marzeptacog alfa (activated) – MarzAA

CATALYST BIOSCIENCES

- Leading next-generation FVIIa with prophylaxis & subcutaneous delivery potential
- 6-9 fold improvements in potency and duration of effect *vs* NovoSeven
- Phase 1 intravenous clinical trial results
  - 25 severe hemophilia patients with and without inhibitors
  - Demonstrated Proof-of-Mechanism
  - Excellent safety and tolerability**
  - No serious drug-related AEs
  - Good correction of PT and aPTT for ~12 h

**http://clinicaltrials.gov/ct2/show/NCT01439971?term=FVIIa&rank=2

Marzeptacog alfa (activated) Potency Advantage

7-fold Increase in Catalytic Activity

Measured by the rate of Factor Xa generation *in vitro*, both in the presence and absence of tissue factor

5-fold Increase in TEG

(Thromboelastography)* Acute peak effect parameters for marzeptacog alfa (activated) 10 μg/kg, were similar to 50 μg/kg wt-FVIIa

6-9-fold Longer Duration of Effect in bleeding study

Single injection of marzeptacog alfa (activated) maintains 50% inhibition of bleeding after tail clip injury for 6-9-fold longer than NovoSeven in hemophilia A mouse

Phase 1 Clinical Trial Data



MarzAA Phase 2 Part of Phase 2/3 SQ Trial

Phase 2 Multi-Dose SQ/ Dose Escalation

- Hemophilia A and B with Inhibitors
- Open label Subcutaneous (SQ) individual dose escalation study, only if a breakthrough bleed occurs
- Up to 12 adult subjects
- **Study initiated**

Phase 2 Clinical Data

- Interim data expected in H1 2018
- Study end points
  - Safety & tolerability of daily SQ dosing
  - Monitoring of potential inhibitor formation
  - Annualized bleed rate (ABR) *vs* recorded historical ABR
  - After 50 exposure days with no bleeds, individuals will move to safety follow-up

Milestones & Planned Data Presentations

CATALYST BIOSCIENCES

	2017			2018			
	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CB 2679d (FIX)	**Phase 1/2** Cohort 1 Completed ✓	**ISTH** Preclin Data 22x Potency Cohort 2 (SQ) Asia Patents US ODD ✓✓✓✓✓	**ASH** Interim SQ Clinical Data (Oral) ✓	**EAHAD** Top-line multi-dose Clinical Data ✓		**ISTH** Final P1/2 Clinical Data **Initiate P2b**	
MarzAA (FVIIa)	**Started** INC, P2 Clinical CRO ✓	**ISTH** Preclinical Data ✓	**Initiate** Phase 2 ✓		**Report** Early P2 Clinical Data	**ISTH** Interim P2 Clinical Data	**ASH** Final Clinical Data

Select Financial Data

CATALYST BIOSCIENCES

Financial Data

Cash as of Sep. 30, 2017[1]	$27.5M
Financing Activity since Sep. 30, 2017:	
- Financing proceeds from December 2017	$9.7M
- Warrants exercised during 2017	$1.3M
Revenue YTD[2]	$0.7M
Operating Expense YTD[2]	$16.7M

Share Data

Shares Outstanding[3]	6,366,604 shares
Series A Preferred[3] (common equivalents)	736,000 shares
Warrants[3]; represents ~$8.0M of proceeds	1,454,295 shares
Average Volume[4]	439,000 shares
Market Capitalization[4]	$205M

1. As of September 30, 2017
2. For the nine months ended September 30, 2017
3. Based upon S-3 Filed January 22, 2018
4. Based on February 9, 2018 $32.15 closing price and Average Nasdaq Volume

CBIO Stock Chart

Stock Price Range

52 week range	$3.11 - $33.81

Investment Highlights

CATALYST BIOSCIENCES

Disruptive approach to a $3.4 Billion market

- **Subcutaneous (SQ) Prophylactic** dosing designed to be less painful and much more convenient, especially for children
- **Stable clotting activity** could dramatically reduce spontaneous bleeding and improve quality of life

FIX: CB 2679d/ISU304 ~$1.2 Billion market

- Confirmed 22-fold potency advantage *vs* BeneFIX
- Median 15.7% FIX activity levels [IQR 14.9-16.6%] reached after 6 daily doses
  - 5/5 severe hemophilia B patients converted to mild hemophilia
- Potential to maintain FIX activity in the mild hemophilia range with less frequent dosing

FVIIa: Marzeptacog alfa (activated) ~$2.2 Billion market

- Phase 2 of a Phase 2/3 program enrolling
- Interim Phase 2 data in 1H 2018

Anti-C3 for Dry AMD: Multi-Billion market opportunity

- C3 is a clinically validated target, potential to generate a best-in-class molecule
- Plan to partner asset

Cash runway through Q2 2019

Catalyst Biosciences

Nasdaq: CBIO

Essential Medicines for Hemophilia • Greater Convenience • Superior Outcomes

www.catalystbiosciences.com

Anti-C3 for GA Dry AMD (dAMD)



- Advanced dAMD, or geographic atrophy (GA), leads to loss of RPE photoreceptors and blindness with no approved drugs
- Global dAMD market is >$5 billion
- C3 is the "best target" in the complement cascade and clinically validated in GA*
  - Apellis' APL-2 (anti-C3 cyclic peptide,15 mg IVT), rP2 (n=246):

    Qmo 29% (p=0.008) inhibition of GA

    Q2mo 20% (p=0.067) inhibition of GA
- **Catalyst's anti-C3 protease program has the potential for best-in-class profile**
  - **May provide superior efficacy with every 3 months (or less frequent) dosing, fewer IVT AEs**

*P. Rosenfeld AAO 2015, Apellis Inc

Anti-C3 Protease for Dry dAMD

Best-in-class Potential

- Catalytic mechanism of action of a protease to inhibit C3 is superior to antibodies and peptides
- Apellis' APL-2 (anti-C3 cyclic peptide, IVT) demonstrated rP2 efficacy with Qmo and potentially Q2mo dosing
- Catalyst's proprietary potent and selective anti-C3 protease leads have demonstrated complete intravitreal C3 inhibition *in vivo* in NHP
- Current CBIO lead suggests Q1-2 month dosing frequency in man at 2 mg IVT
- Modifying the PK could extend human dosing to at least every three months with superior efficacy